2026-10-25
Repligen clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,816 −5.70%
S&P 7,430 −3.37%
GOLD $4,105 +0.80%
BTC $75,995 −5.48%
VIX 25.68 +54.61%
latest tape · as of 16:02 UTC
The Screen · Healthcare · Medical Instruments & Supplies
Repligen Corporation
RGEN · Nasdaq · USD · Market cap $11.4B · 2,000 employees
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Not yet scored178.20 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 16:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price178.20 USD at the 4 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 4 Nov 2026
- Our regime readDistribution, as of 4 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 1.36)
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $121.74 to $140.00, base estimate $121.74 (screen dated 2026-11-04).
- Trend Distribution
- Insiders insiders sold, $1,036,654, latest filing 2026-10-05
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.36, read 2026-11-05
- Ethical screen not yet scored
Price178.20 USD
Fair value121.74
Ethical score70.0/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-11-03Read Markup176.94+0.7% to today ✓Distribution gives way to Markup first Markup read since October
2026-10-21Read Distribution178.88-0.4% to today ✓Markup gives way to Distribution first Distribution read since July
2026-10-11Read Markup177.23+0.5% to today ✓Accumulation gives way to Markup first Markup read since August
2026-09-11Read Accumulation181.69-1.9% to today Markup gives way to Accumulation after a 14% rise in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Repligen Corporation holds its Distribution at $178.20. The statistical read favours the sellers, held for 22 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the sellers, held for 22 days |
| Price at the screen | $178.20 |
| Valuation | N/A trailing · 67.14 forward price to earnings |
| Values screen | Not scored · score 70.0 |
| Beta | 1.12 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 23.39% | Below 33% | Interest-bearing debt is just 23.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 6.83% | Below 33% | Cash held in interest-bearing accounts and securities is 6.8% of assets, under the one-third limit. | Pass |
| Receivables | 24.57% | Below 49% | Money owed to the company is 24.6% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Repligen clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Repligen clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 23%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $121.74 fair value estimate, 10.90% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 46.4% above the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +13% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $121.74, with a range of $121.74 to $140.00, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsPremium Price for Thin Returns in Bioprocessing
Every new biologic drug needs filters and resins to scale from lab to factory. Repligen makes some of those tools, yet the shares trade at 57 times forward earnings while delivering just 7 percent profit margins and 3 percent return on equity. Revenue growth of 15 percent sounds solid until you notice the price already sits 20 percent above our fair value with no clear moat in sight.
We pass because the numbers do not support the multiple. Strong analyst targets sit at 180 dollars, but that optimism cannot hide the low capital returns or the gap between price and value. Ethical checks clear the business, which is the one clean part of the story.
Valuation risk is the real issue here. High expectations baked into the share price leave little margin if growth slows or competition intensifies. Analysis, not advice.
| Forward P/E | 67.1xexpensive even after accounting for its growth |
| EPS, trailing | -0.21 |
| EPS, forward | 2.65 |
| Revenue growth | +10.9%steady growth |
| Profit margin | -1.5%currently unprofitable |
| Return on equity | -0.6%not currently earning a positive return on equity |
| FCF yield | 0.98% |
| Debt to equity | 0.33minimal debt: a conservative balance sheet |
| Current ratio | 9.88comfortably covers its short-term bills |
| Beta | 1.12moves a little more than the market |
| Short interest, float | 0.11% |
| 52-week range | 100.99 - 198.87 |
| Market cap | $11.4B |
| Employees | 2,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeRGEN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-03
Markup · changed $176.94
-1.1% Entry 17
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter.
2026-10-27
Distribution $178.88
+0.0% Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Distribution $178.88
+0.0% Entry 15
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Distribution $178.88
+0.0% Entry 14
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24
Distribution $178.88
+0.0% Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23
Distribution $178.88
+0.0% Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Distribution $178.88
+0.0% Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Distribution · changed $178.88
-2.9% Entry 10
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20
Markup $184.17
+0.0% Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18
Markup $184.17
+3.9% Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (19 analysts) rates it buy, with a mean price target of $179. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook Yahoo Finance · 5d ago
- 5 must-read analyst questions from Repligen’s Q3 earnings call Yahoo Finance · 5d ago
- Repligen Announces $1 Billion Private Convertible Senior Notes Transaction Yahoo Finance · 6d ago
- Repligen Corporation (RGEN) Surges on Revenue Beat and Raised Full-Year Organic Outlook Yahoo Finance · 8d ago
- Repligen Corporation (RGEN) Benefits From Biotech Momentum and Strong Earnings Yahoo Finance · 8d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
AVTRAvantor, Inc.
COOCooper Companies (The)
ALGNAlign Technology
BAXBaxter International
SOLVSolventum
ATRAptarGroup, Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Loeillot Olivier | CEO | S - Sale+OE | 5,535 | $1,036,654 |
| 2026-09-24 | Loeillot Olivier | CEO | S - Sale+OE | 12,946 | $2,459,740 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-08-14 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-08-14 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-08-14 | Ro Khanna | Democrat | buy | 1K–15K |
| 2026-03-30 | Alan Armstrong | Republican | buy | 15K–50K |
| 2026-03-30 | Alan Armstrong | Republican | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $115.91 | +12.9% | · | $1,129 | +12.9% |
| 2 months | $120.10 | +9.0% | · | $1,090 | +9.0% |
| 3 months | $113.76 | +15.1% | · | $1,151 | +15.1% |
| 6 months | $161.66 | -19.0% | · | $810 | -19.0% |
| 1 year | $132.87 | -1.5% | · | $985 | -1.5% |
| 2 years | $141.23 | -7.3% | · | $927 | -7.3% |
| 3 years | $162.19 | -19.3% | · | $807 | -19.3% |
| 5 years | $191.52 | -31.7% | · | $683 | -31.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever RGEN does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.